Completed PHASE2 INTERVENTIONAL 4-arm NCT01117818

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

A Randomized, Controlled, Parallel Group, Double-blind, Multi-center, Phase II Study to Assess the Clinical- and Immunological Activity,as Well as the Safety and Tolerability of Different Doses/Formulations of AFFITOPE AD02 Administered Repeatedly to Patients With Early Alzheimer's Disease

Sponsor: Affiris AG

Conditions Alzheimer's Disease

Interventions active: AFFITOPE AD02 control: Placebo

Updated 6 times since 2017 Last updated: Dec 10, 2013 Started: Sep 30, 2010 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Alzheimer's Disease and is currently completed. Affiris AG leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Affiris AG

Data source: Affiris AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bordeaux, France , Bron, France , Dijon, France , Hall in Tirol, Austria , Hamburg, Germany , Košice, Slovakia , Leipzig, Germany , Linz, Austria , Mannheim, Germany and 14 more locations